Independent Financial Group LLC Makes New Investment in Stryker Corporation $SYK

Independent Financial Group LLC purchased a new position in Stryker Corporation (NYSE:SYK) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,229 shares of the medical technology company’s stock, valued at approximately $732,000.

A number of other institutional investors have also modified their holdings of the business. Vanguard Group Inc. boosted its stake in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. State Street Corp raised its position in shares of Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP boosted its position in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Finally, Norges Bank acquired a new position in Stryker during the 4th quarter valued at approximately $1,822,272,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker Trading Down 1.6%

Shares of SYK stock opened at $313.89 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The stock has a fifty day moving average of $313.79 and a two-hundred day moving average of $336.20. The firm has a market capitalization of $120.33 billion, a PE ratio of 36.33, a price-to-earnings-growth ratio of 2.04 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the business posted $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 14.99 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SYK. BMO Capital Markets started coverage on Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.